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Abstract | CD36 (also known as scavenger receptor B2) is a multifunctional receptor that 
mediates the binding and cellular uptake of long chain fatty acids, oxidized lipids and 
phospholipids, advanced oxidation protein products, thrombospondin and advanced 
glycation end products, and has roles in lipid accumulation, inflammatory signalling, energy 
reprograming, apoptosis and kidney fibrosis. Renal CD36 is mainly expressed in tubular 
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epithelial cells, podocytes and mesangial cells, and is markedly upregulated in the setting of 
chronic kidney disease (CKD). As fatty acids are the preferred energy source for proximal 
tubule cells, a reduction in fatty acid oxidation in CKD affects kidney lipid metabolism by 
disrupting the balance between fatty acid synthesis, uptake and consumption. The outcome 
is intracellular lipid accumulation, which has an important role in the pathogenesis of kidney 
fibrosis. In experimental models, antagonist blocking or genetic knockout of CD36 could 
prevent kidney injury, suggesting that CD36 could be a novel target for therapy. Here, we 
discuss the regulation and post-translational modification of CD36, its role in renal 
pathophysiology and its potential as a biomarker and as a therapeutic target for the 
prevention of kidney fibrosis.   
  
 
[H1] Introduction 
The transmembrane protein CD36 (also known as scavenger receptor B2) has important 
roles in metabolic diseases, including atherosclerosis,1 non-alcholic fatty liver disease2 and 
diabetes melitus3, as well as in metastatic colonization in cancer4. CD36 is ubiquitously 
expressed on the surface of many cell types, including monocytes,5 macrophages,6 
adipocytes,7 myocytes,8 enterocytes9 and hepatocytes2. In the kidney, CD36 is expressed in 
the proximal10 and distal tubular epithelium11, podocytes,12 mesangial cells,13,14 
microvascular endothelial cells and interstitial macrophages15,16. Renal CD36 expression is 
upregulated by hyperlipidaemia and hyperglycaemia, and patients with chronic kidney 
disease (CKD), particularly those with diabetic nephropathy, show increased expression of 
the protein.12,17  
 
CD36 has multiple ligands, which can be classified as lipid-related ligands, such as 
(long-chain) fatty acids,18 oxidized LDL (Ox-LDL),19,20 and oxidized phospholipids21; and as 
protein-related ligands, including advanced oxidation protein products (AOPPs),22 advanced 
glycation end products (AGEs),23 thrombospondin-1 (TSP1), TSP2,24,25 S100 family proteins 
(S100-A8, S100-A926 and S100-A1227), amyloid proteins28,29, and the synthetic 
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growth-hormone-releasing peptide family members hexarelin30 and EP 8031731. Apoptotic 
cells can also act as a ligand for CD3632 (Table 1). Many of these ligands have important roles 
in kidney injury. 
 
The findings of several studies suggest that CD36 serves as a signalling hub for lipid 
homeostasis33,34, immunological responses35, and programming of energy availability36,37. 
CD36 also mediates crosstalk between different cell types — for example between 
macrophages and endothelial cells or between tubular cells and macrophages or 
myofibroblasts — in response to oxidized ligands such as Ox-LDL, oxidized phospholipids, 
apoptotic cells and AOPPs.38 In proximal tubular epithelial cells (PTECs), CD36 is involved in 
energy source regulation via mitochondrial β-oxidation of fatty acids, which are a major 
source of renal ATP production.39 
 
Disruption of any of the above mentioned CD36-dependent pathways, such as defective 
fatty oxidation in PTECs, has a critical role in the development of kidney fibrosis.40 In mice, 
blocking CD36 prevents CKD progression,41 demonstrating an important role of CD36 in 
renal injury and its potential as a therapeutic target. In this Review, we focus on the 
biological, physiological, and pathological roles of CD36 that might promote CKD progression, 
namely roles in lipid homeostasis, metabolic inflammation, apoptosis, and reprogramming 
of energy metabolism.  
 
[H1] The CD36 gene 
The human CD36 gene is ~46 kb in length and is located on chromosome 7q11.2. The gene 
has 15 exons; exons 4 to 13 and part of exons 3 and 14 encode the CD36 protein.42  
Mutations in the CD36 gene are linked to abnormalities of plasma fatty acids and 
triglycerides, which are risk factors for metabolic diseases involving insulin resistance.43  
[H2] Transcriptional regulation 
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The CD36 gene promoter contains CCAAT/enhancer-binding protein (C/EBP) responsive 
elements, which enable C/EBP to bind and regulate CD36 expression in various cell types.7 
Nuclear receptors also have important roles in the transcription of the CD36 gene. For 
example, peroxisome proliferator-activated receptor α (PPAR-α) and PPAR-γ have been 
shown to regulate CD36 expression in human macrophages44 and cardiac microvascular 
endothelial cells45. In addition, study have shown that PPARγ dependent pathway increase 
CD36 expression can be activated by high glucose in the human HK-2 proximal tubular cell 
line.46,47 Whether or not the CD36 promoter contains a PPAR responsive element, however, 
remains unclear. Response element binding sites for Pregnane X receptor (PXR) and liver X 
receptor (LXR) have been identified in the CD36 promoter, and activation these receptors 
could upregulate CD36 expression and promote hepatic steatosis .33  However, LXR 
activation in diabetic kidney models was determined to be renoprotective through 
mechanisms independent of CD36 but expression levels were not examined in all 
studies.48-50 
Lipids including fatty acids12, and Ox-LDL51 can upregulate CD36 expression. Following 
CD36-mediated uptake in macrophages, Ox-LDL is metabolized to produce 9-hydroxy 
octade-cadienoic acid and 13-octade-cadienoic acid. These metabolites are PPAR agonists 
that activate PPAR through protein kinase C (PKC), protein kinase B and p38 
mitogen-activated protein kinase (MAPK) pathways. Following activation, PPAR and retinoid 
X receptor form a heterodimer that binds to the CD36 promoter and increases CD36 
transcription.52 In turn, increased expression of CD36 leads to an increase in Ox-LDL uptake 
in macrophages and promotes foam cell formation.53 In contrast to Ox-LDL, oxidized HDL 
(Ox-HDL) inhibits macrophage CD36 expression via PPAR-dependent mechanisms.54  
Lysophosphatidic acid (LPA) is a central component of cellular phospholipid metabolism and 
an important regulator of vascular remodelling and inflammation.55 LPA downregulates 
CD36 transcription in microvascular endothelial cells via a protein kinase D1 
(PKD1)-dependent pathway.56 LPA/PKD1-induced downregulation of CD36 in these cells is 
mediated by nuclear accumulation of histone deacetylase 7, which interacts with forkhead 
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box protein O1 to suppress CD36 transcription57. In microvascular endothelial cells, 
LPA/PKD-1 signalling activated a transcriptional proangiogenic switch involving ephrin B2, 
which is a critical mediator of angiogenesis and arteriogenesis.57  
In addition to lipids, high glucose levels and insulin have been reported to induce the 
expression of CD36 in mesangial cells58 and cardiac myocytes59, respectively. 
Monocyte-colony stimulating factor60, phorbol ester61, tumour necrosis factor (TNF) 62, IL-463 
and thiazolidinediones64,65 can also promote CD36 expression in monocyte/macropahges. By 
contrast, lipopolysaccharide66, dexamethasone60, interferon67, transforming growth factor 
(TGF)-β1/268, tamoxifen69, and HDL70 inhibit macrophage CD36 expression, whereas statin 
treatment has been reported to substantially reduce platelet CD36 expression.71 
 
[H1] The CD36 protein 
Full-length human CD36 comprises around 472 amino acids and has a predicted molecular 
mass of 53 kDa.72 The protein has two transmembrane domains with a huge extracellular 
region, which contains the ligand-binding region, and two short cytoplasmic tails at the 
N-terminus and C-terminus.42,73 The extracellular loop contains a large hydrophobic cavity 
that traverses the entire length of the molecule. This cavity is thought to serve as a tunnel 
through which hydrophobic ligands (including cholesterol and fatty acids) are delivered from 
the extracellular space to the outer leaflet of the plasma membrane74 (FIG. 1).  
CD36 also has a positively charged domain (155–183 amino acids contain lysine cluster) that 
binds negatively charged ligands.75 Almost all end-stage biological oxidation products are 
negatively charged, including Ox-LDL, AOPPs, AGEs, and apoptotic cells. Binding of these 
ligands, which are markers of cellular oxidative stress and denaturation of lipids or proteins, 
to CD36 triggers pathophysiological responses such as inflammatory and proatherogenic 
processes.15,23,53  CD36 has been shown to interact with TSP1 through electrostatic forces 
mediated by the multiple negatively charged CD36, LIMP-2, Emp sequence homology 
domain (CLESH) residues of CD36 and the positively charged surface of the thrombospondin 
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type I repeat 2 domain of TSP176. This interaction is required for the CD36 CLESH-dependent 
anti-angiogenic activity of TSP1.   
Previous studies indicated that circulating soluble CD36 (sCD36) consists of part of the 
extracellular segment of CD36.77,78 The huge CD36 extracellular segment might undergo a 
‘cut-down' process by a plasma protease, resulting in release of sCD36 into the circulation.78 
Driscoll and colleagues demonstrated that ADAM17 mediates proteolytic cleavage of the 
CD36 extracellular domain, which might be a mechanism to regulate efferocytosis or 
clearance of apoptotic cells.79 However, another group reported that sCD36 is not a 
‘cut-down’ product from extracellular domain, more likely is a specific subset of circulating 
microparticles.80 Thus, the mechanism by which sCD36 is formed is not clear and more 
studies are need for this confusion. 
[H2] Post-translational modifications 
Post-translational modifications might have an important role in regulating CD36 location 
and function. In general, glycosylation, ubiquitination, and palmitoylation are involved in 
regulating CD36 stability, protein folding, and trafficking, whereas phosphorylation at 
extracellular sites affects the rate of ligand (such as fatty acid) uptake.81 Acetylation of CD36 
has also been reported,82,83 but the effects of this modification on CD36 expression and 
function have not yet been elucidated. 
[H3] Phosphorylation. CD36 has two phosphorylation sites at Thr92 and Ser237, both of 
which modulate ligand binding within the extracellular loop. The Thr92 site is a putative PKC 
bindingsite, whereas the Ser237 site is recognized by PKA.84,85 Phosphorylation of these sites 
is positively linked to CD36 function possibly through the modulation of ligand binding.  
In platelets, phosphorylation and dephosphorylation of CD36 on the cell membrane affects 
TSP binding and controls collagen adhesion.85 In vitro cell free condition, inhibition of TSP 
binding to CD36 was correlated with level of Thr92 phosphorylation of CD36.86In addition, 
this site phosphorylation occurred during the process of new protein synthesis and 
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trafficking through the Golgi.86 Phosphorylation of CD36 at Thr92 is also necessary for 
binding of CD36 to erythrocytes that are infected by Plasmodium falciparum.87 
Phosphorylation of CD36 at Ser237 has been reported to inhibit fatty acid uptake in 
platelets and enterocytes88,89. Whether such CD36 phosphorylation also leads to inhibition 
of fatty acid uptake in the kidney has not yet been investigated. 
[H3] Glycosylation. The process of glycosylation occurs within the endoplasmic reticulum 
(ER) and the Golgi, where it provides stable coupling of complex oligosaccharide structures 
to proteins.90 The majority of glycosylation is N-linked at asparagine residues.91  CD36 has 
10 potential glycosylation sites, all of which are located within the extracellular loop,  and 
fully glycosylated CD36 is an approximately 88 kDa transmembrane glycoprotein receptor72. 
Glycosylation of CD36 is a hydrophilic modification, which is very important for protein 
folding, stability, and trafficking, but does not affect ligand binding.91 In intestinal 
enterocytes, enhanced CD36 glycosylation reportedly results in an increase in the absorption 
of fatty acids by unknown mechanisms.9  
In spontaneously hypertensive (SHR) rats, CD36 is mutated at multiple sites including 
Asp102, which is located within the fatty acid binding pocket and is a potential 
N-glycosylation site.92 In the hearts of these rats, both total CD36 protein expression and 
fatty acid utilization were significantly reduced, perhaps owing to a decrease in CD36 
stability as a result of the mutation at Asp102.92 Further studies are needed to investigate 
the role of glycosylation in altered fatty acid uptake in CKD. 
[H3] Palmitoylation. Palmitoylation regulates the subcellular localization, membrane 
interactions, and subcellular trafficking of proteins. CD36 has four palmitoylation sites, 
which are located in the third, seventh, 464th and 466th cysteine residues in the 
cytoplasmic segment of the N-terminal and C-terminal.93  Palmitoylation of CD36 is a 
reversible catalytic process. In most cases the reversible covalent bond occurs between 
palmitate and cysteine residues via a thioester linkage. Protein palmitoylation requires 
palmitoyl-transferases (PATs) and palmitoyl-protein thioesterases (PPTs) for palmitoylation 
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and depalmitoylation, respectively.94 Under palmitic acid stimulation, PATs cause CD36 
palmitoylation in the ER.93,95  
Palmitoylated CD36 is located in the lipid rafts of the cell membrane where it mediates 
adsorption and transport of fatty acids.96 Inhibition of palmitoylation stops the maturation 
of CD36 and causes CD36 precursor proteins to remain in the ER.95 Non-palmitoylated CD36 
has a short half-life as it is more likely to be degraded than palmitoylated CD36.95  
Palmitoylation of CD36 might, therefore, have a role in lipid accumulation. Inhibition  of 
CD36 palmitoylation might be a potential strategy to reduce CD36-mediated lipid 
accumulation and inflammatory signalling; however, whether such palmitoylation occurs in 
renal cells has not been determined.  
[H3] Ubiquitination. The polyubiquitination pathway targets proteins for proteasomal 
degradation. CD36 has two ubiquitination sites in the C-terminus at Lys469 and Lys472 that 
are responsible for its regulation by polyubiquitination.97 In C2C12 myotubes, the degree of 
polyubiquitination of CD36 did not affect the relative distribution of the protein between 
the intracellular storage compartments and thecell surface, but down-regulate protein 
expression level97. 
Platelet-derived exosomes increase the polyubiquitination of CD36 and enhance 
proteasome degradation.98 In a mouse muscle cell line (C2C12), oleic acid increased, 
whereas insulin decreased the polyubiquitination of CD36.97 Concomitantly, fatty acids 
reduce CD36 protein levels and decrease cellular fatty acid uptake, whereas insulin has the 
opposite effect.97  
In contrast to polyubiquitination, mono-ubiquitination is considered to be non-degradative 
and has other functions such as protein complex formation. The intracellular C-terminal 
lysines in CD36 can be targeted by parkin, which has E3 ubiquitin-protein ligase activity and 
participates in the process of protein ubiquitination. 99 In mice, a high-fat diet increased 
hepatic parkin and CD36 levels, which contributed to increased lipid accumulation and 
insulin resistance.100 Parkin-knockout mice on a high fat diet had reduced hepatic CD36 
 9 / 43 
 
levels that blunted the maladaptive response to lipid metabolism and insulin signalling 
compared with controls.  
High-fat diet increased Parkin levels and CD36 levels in liver of mice, suggesting that fatty 
acids should stabilize or increase the CD36 protein level via Parkin-mediated 
mono-ubiquitination.100 Indeed, fatty-acid-mediated polyubiquitination and degradation of 
CD36 in C2C12 myotubes cell lines.97,100  and can be explained by the fact that parkin 
exhibits both mono-ubiquitination and polyubiquitination functions.101 Hence, the 
downstream effects of parkin can be both dependent and independent of the proteasome. 
The function of parkin might vary between different tissues and conditions such that it 
operates as a mono-ubiquitinase in some settings and as a polyubiquitinase in others. The 
role of fatty acids in CD36 degradation in the kidney remains unclear. 
[H3] Acetylation. Protein acetylation has roles in cell apoptosis102, subcellular protein 
localization103, glucose and FA metabolism82 DNA and protein interactions, DNA replication 
and repair, DNA transcriptional activity and protein stability104. Acetylation of CD36 at Lys52, 
Lys166, Lys231 and Lys403 has been shown using mass spectrometry82,83, but the biological 
effects of this acetylation remain unclear. 
[H2] Cellular location 
CD36 is not only present at the cell surface but also in endosomes, the ER and 
mitochondria.105 The protein can migrate between these locations via vesicular transport 
along exocytotic and endocytotic pathways to control lipid homeostasis and energy 
reprogramming2,59,106-108(FIG. 3). A net translocation of CD36 to the plasma membrane is 
induced by several physiological stimuli, most notably elevated circulating insulin levels106, 
muscle contraction109.  
Insulin-induced CD36 translocation requires activation of the phosphatidylinositol-3-kinase–
Akt2 signalling axis,59,106 whereas muscle-contraction-induced CD36 translocation is 
dependent on activation of AMP-activated kinase (AMPK).109,110 Inflammation increases 
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CD36 transcription, translation, and translocation to the cell surface.96 Post-translational 
modifications could be major factors that determine the cellular location and function of 
CD36. 
High molecular weight CD36 homodimers and oligomers have been detected in human 
platelets and in COS-7 cells transfected with human CD36.24,111 G12xxxG16xxxA20 and 
A20xxG23 motifs in the N-terminal transmembrane domain of CD36 are responsible for its 
dimerization112. Whether homodimerization of CD36 and palmitoylation of cysteine residues 
close to the N-terminal region affects its function, cellular location, ligand binding and signal 
transduction remains unclear.  
[H1] Roles of CD36 in renal pathophysiology 
CD36 modulates multiple pathways that have important roles in acute kidney injury(AKI) and 
CKD. 
 
[H2] Fatty acid accumulation 
The lipid nephrotoxicity hypothesis, which was first proposed by Moorhead et al. in 1982113 
and updated by Ruan et al. in 2009114, suggests that. This concept has led to a large number 
of studies focusing on the relationship between lipids and renal disease. Evidence from 
experimental animals and from humans suggests a direct role of lipids, including 
non-esterified fatty acids, triacylglycerols and cholesterol, in the initiation and progression 
of CKD.115 
 
The total lipid content of the healthy human kidney is estimated to comprise approximately 
3% of the wet weight.116  More than half of this lipid content is phospholipids, 
approximately one-fifth is triglycerides, and about one-tenth is non-esterified fatty acids 
(NEFAs).117 In vivo studies using radiolabelled fatty acids in dogs118, as well as analysis of 
differences in substrate (including fatty acids, lactate, citrate and pyruvate) levels  between 
human arterial and renal venous blood116, have indicated that the kidney extracts fatty acids 
from the circulation, and that fatty-acid oxidation could account for more than half of renal 
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oxygen consumption. Importantly, fatty acid extraction by the human kidney in vivo was 
linearly dependent on plasma fatty acid concentrations.116  
 
Kidney uptake of circulating fatty acids requires dissociation from albumin, which is 
mediated by specific membrane proteins such as CD36.119 The renal proximal tubule 
retrieves albumin-bound fatty acids from the filtrate by CD36 or receptor-mediated albumin 
endocytosis.120 In mice, the kidney takes up NEFAs and increases fatty acid oxidation (FAO) 
during fasting states, whereas de novo lipid synthesis pathways are downregulated121. 
Similar to the liver and in contrast to muscle, CD36 and lipoprotein lipase are not required 
for uptake of NEFAs in the normal murine kidney121. These findings do not, however, rule out 
a role of CD36 in fatty acid transport in the kidney as CD36 does not have a role in the 
passive transmembrane movement of fatty acids,105 which might be an important mode of 
fatty acid uptake during fasting. 
 
As fatty acids are the preferred energy source for PTECs, a reduction in FAO in CKD affects 
kidney lipid metabolism by disrupting the balance between fatty acid synthesis, uptake and 
consumption.40 The outcome is intracellular lipid accumulation, which has an important role 
in the pathogenesis of kidney fibrosis.40  
 
In the settings of murine and human CKD, genes that are associated with FAO are 
downregulated in the kidney.40 Kidney biopsy samples from patients with diabetic 
nephropathy showed lipid accumulation in the glomeruli and tubulointerstitium together 
with upregulation of CD36 compared to normal control samples.12,17 Transgenic 
overexpression of tubular CD36 lead to increase intrarenal lipid accumulation but only a 
slight increase in profibrotic genes in the absence of kidney injury and did not show any 
difference in fibrosis.40,122 In podocytes, CD36-dependent uptake of palmitic acid led to a 
dose-dependent increase in the levels of mitochondrial reactive oxygen species (ROS), 
depolarization of mitochondria, ATP depletion, and apoptosis.12,28 Moreover, studies in 
mouse models have shown that in the setting of CKD, CD36 promotes fibrogenesis by 
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increasing oxidative stress and activating proinflammatory pathways, although the role of 
CD36 in FAO was not investigated.123  
 
Further research is required to identify the differential roles of passive and active fatty acid 
transport in kidney disease as well as the major receptors that are involved in fatty acid 
uptake in the kidney. Such studies will enable greater insight into the mechanisms of fatty 
acid metabolic dysfunction in kidney disease.   
 
[H2] Interactions with oxidized lipids   
Accumulation of Ox-LDL in the circulation and renal interstitium has been reported in 
experimental models and in patients with CKD and end-stage renal disease (ESRD).124,125 
Macrophage CD36 can bind large amounts of Ox-LDL and mediates the endocytosis and 
degradation of Ox-LDL in vivo; some studies have reported that CD36 is responsible for 
more than half of Ox-LDL uptake in macropahges126  
 
In hypercholesterolemic mice with kidney injury (as a result of unilateral ureteral 
obstruction), Ox-LDL deposition was evident in the renal tubules and interstitial 
compartment and correlated with fibrosis.11 CD36 deficiency in the same model reduced the 
activation of proinflammatory and oxidative pathways, resulting in a substantial reduction in 
the number of interstitial myofibroblasts compared with wild-type controls.123 Even in 
normocholesterolemic states, however, chronic kidney injury results in the de novo 
generation of intracellular oxidized lipids in macrophages.126  
 
In a mouse model of renal fibrosis induced by unilateral ureteral obstruction, lipid 
metabolism led to a twofold to sixfold increase in the levels of the intracellular lipid 
peroxides hydroxyoctadecadienoic acid (HODE) and hydroxyeicosatetraenoic acid (HETE) in 
CD36+renal macrophages.126 The absence of macrophage CD36 expression in this model led 
to a 50% reduction in the intracellular levels of HODE and HETE, reduced fibrosis and 
preservation of kidney function. In this nonproteinuric model of CKD, macrophage CD36 
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formed a heterodimer with Lyn kinase at its C-terminus to activate a NF-κB 
p50p65-dependent proinflammatory pathway.126  
 
Activation of NF-κB increases the production of proinflammatory cytokines and chemokines, 
which might trigger an influx of monocytes and accumulation of macrophages in the 
kidney.41 In proximal tubular cells, CD36 heterodimerizes with the Na+/K+-ATPase α-1 
subunit in response to Ox-LDL or ouabain15. This heterodimer activates Src and Lyn kinases 
and can potentiate a proinflammatory signaling loop involving TNF, CC motif chemokine 2 
and IL-6.15  Moreover, Ox-LDL or ouabain induced ROS production in proximal tubular cells 
was significantly attenuated by knockdown of the Na+/K+-ATPase α-1 subunit or 
N-acetyl-cysteine. These facts suggsting that CD36 and the Na+/K+-ATPase share ligands and 
downstream molecular cross-talk in kidney and they act synergistically to promote 
inflammation in hyperlipidemic states.15 Sheedy et al. found that sustaining uptake of 
Ox-LDL by CD36 causes the nucleation and accrual NLRP3-activating crystals within the 
macrophage, and induced the release of IL-1β.127  
 
HDL is susceptible to structural modifications, including oxidation, in the setting of metabolic 
disorders.128,129 Oxidative modification of HDL (Ox-HDL) has been reported in patients with 
advanced-stage renal disease, particularly in those with diabetic nephropathy.130 The levels 
of oxidized phospholipids was also significantly increased in apoptotic cells in an 
experimental CKD model.126 In human renal tubular (HK-2) and mesangial cells, binding of 
Ox-HDL to CD36 enhanced ROS production and upregulated the expression of 
proinflammatory factors via activation of p38/MAPK, extracellular-regulated kinase 
(ERK)/MAPK and NF-κB.131 Src family kinase was also activated in HK-2 cells following 
stimulation with Ox-HDL, and apoptosis was increased.131 
 
[H2] Endocytosis of AOPPs 
AOPPs are a family of oxidized, dityrosine-containing, cross-linked protein compounds that 
are formed by the reaction of plasma proteins with chlorinated oxidants. Studies suggest 
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that AOPPs are important renal pathogenic mediators in the progression of CKD and 
associated cardiovascular disease.132,133 CD36 is a receptor for AOPP-modified albumin in 
proximal tubular cells.22 Moreover, anti-CD36 antibody treatment has been shown to inhibit 
oxidant-damaged human serum albumin (AOPPs-HSA)-induced endocytic association and 
degradation of AOPPs in HK-2 cells22. AOPPs-HSA increased intracellular ROS generation and 
TGF-β1 secretion in these cells, whereas anti-CD36 antibody abrogated AOPPs-HSA-induced 
up-regulation of TGF-β1.22  
 
CD36 binding of AOPPs activates the renin–angiotensin system in proximal tubular NRK52E 
cells via PKCα/NADPH-dependent activation of NF-kB.134 Blocking CD36, PKCα or NADPH 
oxidase dramatically abolished AOPP-augmented activation of AP-1 and NF-kB in these cells, 
suggesting that AOPPs activate NF-kB and AP-1 through the CD36-PKCα-NADPH oxidase 
pathway.134 
 
[H2] Interactions with thrombospondin 1  
TSP1 is a matricellular protein that inhibits angiogenesis and causes apoptosis in vivo and in 
vitro in several cells and tissues. Interaction of TSP1 with CD36 is critical for activation of 
latent TGF-β and might be involved in initiating and regulating cellular fibrosis.135 TSP1 and 
CD36 are induced early in renal ischaemic-reperfusion injury (IRI) and TSP1-null mice 
showed substantial preservation of kidney function after IRI.136  In rodent kidneys 
subjected to IRI, formation of the TSP1–CD36 complex in proximal tubular cells led to 
cleavage of caspase 3 and apoptosis.136 Similarly, in an adriamycin-induced nephropathy 
mouse model of focal segmental glomerulosclerosis, TSP1 expression increased in injured 
podocytes and led to CD36-dependent apoptosis via activation of the p38MAPK pathway.137  
 
In a model of diet-induced obesity, podocyte apoptosis and dysfunction were attenuated in 
TSP1-deficient and in CD36-deficient mice, suggesting that the interaction of TSP1 with 
CD36 contributes to obesity-associated podocytopathy138. Moreover, blocking TSP1 binding 
to CD36 using peptide treatment attenuated fatty-acid-induced podocyte apoptosis, 
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suggesting that the TSP1/CD36 interaction mediates this process. 
 
The antiangiogenic effects of TSP1 and TSP2 are mediated through binding to microvascular 
CD36 as evidenced by the finding that TSP1 and TSP2 do not inhibit neoangiogenesis in 
CD36-/- mice.139,140 LPA has been shown to downregulate CD36 transcription via protein 
kinase D1 (PKD1) and antagonize the antiangiogenics effect of TSP1 and TSP2.56  
 
[H2] Endocytosis of AGEs 
AGEs are a heterogeneous and complex group of compounds that have an important role in 
the development of diabetic nephropathy. Using Chinese hamster ovary cells that 
overexpressed CD36, Ohgami et al. made the interesting discovery that AGEs are recognized 
by CD36, endocytosed in a dose-dependent fashion and undergo lysosomal degradation.6  
 
AGE–BSA [Au: bovine serum albumin? Yes] upregulated CD36 expression and lipid uptake 
in monocytes from patients with diabetes and in aortic vascular smooth muscle cells from 
diabetic rats.141-143 AGE-LDL has been shown to potentially induce production of 
proinflammatory cytokines by interacting with CD36 in mouse monocytes.144 Moreover, 
early work from Suztak and colleagues demonstrated that CD36 expression is necessary and 
sufficient to mediate apoptosis of PTECs induced by AGEs and fatty acids through sequential 
activation of Src kinase, p38MAPK and caspase 3.10 
 
[H2] Amyloid deposition 
Deposition of amyloid fibrils derived from serum amyloid A protein (SAA) causes systemic 
amyloid A (AA) amyloidosis, which is a serious complication of chronic inflammatory 
conditions. The kidney is one of the organs that is most often affected by AA amyloidosis. 
Renal AA amyloidosis leads to progressive deterioration of renal function and is considered 
to be intractable.145 CD36 is a receptor for SAA23 and has been reported to have a role in 
SAA-induced proinflammatory activation through JNK and ERK1/2-mediated signalling in the 
HEK293 human embryonic kidney cell line.108 This finding suggests that CD36 has an 
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important role in the initiation of inflammatory reactions and oxidative stress in renal AA 
amyloidosis. Further exploration of the role of CD36 in this disease would, therefore, be of 
interest. 
 
[H2] Other activators of CD36 
In HK-2 cells, high glucose levels increased CD36 expression in a time-dependent manner 
and induced epithelial-to-mesenchymal transition at 72 h.146  This effect could be 
prevented either by knockdown of CD36 or by treatment with the CD36 antagonist 
sulfosuccinimidyl-oleate.146 Studies using a proximal tubular cell line (LLC-PK1 cells) showed 
that albuminuria enhanced the secretion of bioactive TGF-β and fibronectin and 
upregulated CD36122. Treatment with CD36 siRNA abrogated these increases, suggesting 
potential anti-fibrotic effects. 
 
[H2] CD36 signalling and kidney injury   
CD36 is able to generate cell-specific responses to multiple ligands through the binding of 
context-specific binding partners (such as toll-like receptor 2 (TLR2),147 TLR4, TLR6,148 149 13 
150 131 tetraspanin CD9, 151 integrin152,153 and Na+/K+ATPase) and to activate NF-kB154, 
NLRP3127, PKC-NAPDH oxidase,134 Src/Lyn/Fyn and MAPK kinases131, and TGF-β22 signalling 
pathways (FIG. 2). These effects result in metabolic inflammation, energy reprogramming, 
apoptosis and fibrosis, which contribute to the development of renal injury. 
 
Fatty acids and Ox-LDL increase the apoptosis of human macrophages.19,155 In ER-stressed 
murine macrophages, oxidized phospholipids, Ox-LDL, saturated fatty acids, and 
lipoprotein(a) have been shown to trigger apoptosis via an interaction between CD36 and 
TLR2/TLR6 heterodimers.21 When exposed to Ox-LDL and amyloid β, CD36 forms 
heterodimers with TLR4 and TLR6 via its C-terminus Tyr463, and CD36-Lyn kinase interaction, 
causing inflammatory responses.149 The interactions of CD36 with TLR2,147 tetraspanin151 
and integrins152,153 contribute to Ox-LDL uptake and foam cell formation in atherosclerosis. 
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Whether all CD36 ligands have similar effects on binding partners, downstream signal 
transduction pathways and their biological effects in the kidney is unclear as are the 
mechanisms by which CD36 senses different ligands and exerts specific responses. The 
specific effects of crosstalk between CD36 ligands, binding partners and signal pathways on 
inflammation, apoptosis, and especially energy reprogramming in the kidney, warrant 
further investigation. 
 
Macrophage infiltration into the kidney has an important role in CKD. Increased CD36 
expression has been observed in the kidneys and peripheral blood monocytes of patients 
and mice with chronic renal failure.156,157 5 158 Moreover, in mouse models of unilateral 
ureteral obstruction and ischaemia reperfusion, knockout of CD36 in monocytes decreased 
the severity of fibrosis and improved kidney function.126 The role of CD36 in crosstalk 
between macrophages and kidney cells and in the initiation and amplification of 
inflammation, apoptosis and fibrosis required further investigation. 
 
[H2] Energy reprogramming 
Mitochondrial β-oxidation of fatty acids is a primary source of renal ATP production, 
particularly in the proximal tubule, which has a high-energy demand and relatively low 
glycolytic capacity, suggesting that fatty acids are the preferred energy source for proximal 
tubule cells.39 A reduction in fatty acid oxidation in CKD would affect lipid metabolism by 
disrupting the balance between fatty acid synthesis, uptake, and consumption, leading to 
dysregulated intracellular lipid accumulation, which has a crucial role in the pathogenesis of 
kidney fibrosis.159  
 
Metabolic reprogramming is characterized by decreased expression of key enzymes and 
regulators of FAO and increased intracellular lipid deposition. Inhibition of FAO in tubular 
epithelial cells in vitro causes ATP depletion, cell death, de-differentiation, and intracellular 
lipid deposition.40     
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Diabetic complications have been shown to arise in the context of distinct tissue-specific 
alterations in metabolism160. In the diabetic kidney, substrate utilization progressively 
increased with simultaneous consumption of glucose and fatty acids, suggesting that 
metabolic reprogramming with enhanced protein acetylation led to mitochondrial 
dysfunction.160 Increasing amounts of fatty acid bound to albumin lead to defects in 
mitochondrial respiration and to peroxide-mediated apoptosis of tubular cells.161 Compared 
to people with normal kidney function, patients with CKD had markedly lower 
transcriptional levels of genes related to fatty acid metabolism and their key transcriptional 
regulator complex PPARα–PPARr co-activator 1-α (PGC-1α).40 Moreover, proximal tubular 
cells with defective fatty acid oxidation showed fibrosis phenotypes with ATP depletion, 
increased cell death, dedifferentiation and intracellular lipid deposition.40 Thus, restoring 
metabolic defects in fatty acid oxidation might be a potential therapeutic strategy for CKD 
(FIG. 3).    
 
Mitochondrial transfer of fatty acids is the rate-limiting step in fatty acid oxidation. This 
transfer requires linking of fatty acid products to carnitine via carnitine palmitoyltransferase 
1 (CPT1) and CPT2.162  The mitochondrial enzyme carnitine O-acetyltransferase (CRAT) 
complexes excess acyl groups to carnitine, enabling them to exit the mitochondria163. The 
importance of CD36 in FAO has been suggested to relate to its function in mitochondrial 
transfer of fatty acids, which has been demonstrated in human skeletal muscle cells.16,162 
CD36 was identified in purified mitochondria from these cells and was shown to 
co-immunoprecipitate with CPT1. In addition, increased mitochondrial CD36 content 
paralleled up-regulation of fatty acid oxidation in skeletal muscle.16,162  
 
CD36 might have a similar function in mitochondrial fatty acid transfer in PTECs, which also 
have a high energy demand. PTECs express high levels of CPT1A, CPT1B, and CPT2 and 
CRAT.164 In contrast to CRAT in the liver and skeletal muscle, which can be both 
mitochondrial and peroxisomal, renal CRAT is almost exclusively mitochondrial.165 Any 
alterations in CPT1 activity will likely affect fatty acid metabolism and oxidation in proximal 
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tubular cells. Deletion of CPT1B in the heart causes cardiac hypertrophy and death,166 
whereas inhibition of CPT1 in the liver leads to steatosis.167 These findings suggest that CPT1 
control of FAO has profound implications for cellular energy balance. In the kidney, too little 
CPT1 expression accompanied by decreases in the levels of other enzymes with roles in FAO 
might lead to an energetic crisis and potentially result in tubulointerstitial fibrosis. 
 
The role of CD36 in FAO seems to be linked to inter-regulation of CD36 and AMPK. In the 
heart, AMPK functions as an important energy sensor and metabolic regulator that is 
activated in response to increasing energy demand and upregulates nutrient uptake, and 
catabolism.168 AMPK enhances fatty acid oxidation by reducing the levels of malonyl-CoA via 
phosphorylation and inactivation of acetyl-CoA carboxylase.169 In cardiac myocytes, CD36 
co-ordinates dynamic protein interactions within a molecular complex consisting of CD36, 
Fyn kinase, LKB1 and AMPK.36  In the setting of low fatty acid concentrations, CD36 
expression maintains AMPK quiescent by enabling Fyn to access and phosphorylate LKB1, 
promoting its nuclear sequestration away from AMPK, resulting in inhibition of AMPK and 
consequently of AMPK-mediated FAO.36 However, high levels of palmitate binding to CD36 
activate AMPK within minutes via its ability to dissociate Fyn from the complex as CD36 is 
internalized into LKB1-rich vesicles.36 The ensuing enrichment in cytosolic LKB1 levels 
activates AMPK, which enhances FAO by inactivating acetyl-CoA carboxylase.36  AMPK 
activation also induces cell surface CD36 recruitment in myocytes.170 This dual effect would 
serve to adjust the capacity for fatty acid oxidation to match fatty acid availability and 
balance on energy saving and usage.171  
 
Dysregulation of AMPK signalling172 or CD36 deletion in myocytes173 is associated with 
metabolic inflexibility evidenced by a diminished capacity to adjust FAO to fatty acid 
availability. Whether these mechanisms also occur in the proximal tubule during kidney 
disease is currently unknown. However, targeted deletion of LKB1 in distal tubular cells 
resulted in renal fibrosis by  significantly reduced the levels of key effectors of FAO, such as 
AMPK, PGC-1α, and PPARα.174 Moreover, Suztak and colleagues demonstrated that free 
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palmitic acid leads to CD36-dependent proximal tubule apoptosis via activation of the p38 
MAPK pathway.10 These results could suggest that the CD36–LKB1 pathways are important 
in promoting metabolic dysfunction in tubular cells during CKD. 
 
[H1] Soluble CD36 —a potential biomarker     
Evidence suggests that sCD36 might have a role in modulating the immune response by 
binding to TLR2.77 The levels of sCD36 correlate with tissue CD36 expression.175  Use of 
HMG-CoA reductase inhibitors (statins) has been reported to affect sCD36 levels by 
unknown mechanisms.176  
 
Several studies have suggested that sCD36 might be a valuable biomarker of disease activity 
in several chronic inflammatory diseases, including diabetes, non-alcoholic steatohepatitis 
and atherosclerosis.177-181 In some clinical studies, serum levels of sCD36 positively and 
significantly correlated with body weight, BMI, waist circumference, monocyte counts and 
the levels of cholesterol and LDL.182,183  In patients with stage 5 CKD (n = 228) on dialysis, 
serum sCD36 levels were significantly increased and predicted cardiovascular mortality.176 
Several studies have analysed sCD36 levels in plasma samples; however, these samples have 
to potential to skew interpretation of the results owing to the presence of CD36 in platelets, 
which could represent a marker of platelet activation.177,184,185 Furthermore, microparticles 
that are released upon platelet activation might represent an important source of CD36.  
 
The available evidence indicates a close relationship between CD36 and kidney disease 
progression. However, the various commercial assays for sCD36 provide inconsistent 
results.186 Further studies are needed with standardized and appropriate methods to 
validate the use of sCD36 as a biomarker in diabetes and CKD.  
 
[H1] CD36 as a potential therapeutic target 
CKD is a global health problem with no therapeutic options beyond 
angiotensin-converting-enzyme inhibitors to slow its relentless progression.187,188 The 
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multi-ligand potential and multi-functionality of CD36 make it an attractive target for 
blocking kidney injury and subsequent progressive loss of kidney function. Several studies 
have demonstrated that blockade or deficiency of CD36 can block fibrosis pathways, 
metabolic dysfunction and proteinuria.41,122,123,126  
 
[H2] CD36 blockade 
CD36-deficient mice develop low-grade proteinuria owing to loss of CD36-mediated albumin 
and other protein uptake in proximal tubules,189 without the formation of fibrosis in aged 
mice. Furthermore, silencing or antibody blockade of CD36 in PTECs exposed to AOPPs in 
vitro blocked TGF-β production,22 and suggests that CD36 is an important mediator of 
proteinuric injury. In addition to tubules, CD36 is also upregulated in podocytes during 
proteinuric injury in experimental models and human podocytes, and blockade of CD36 on 
podocytes in vitro led to an improvement in health with less apoptosis and oxidative 
stress.12,22,137,138,190 Blockade of CD36-dependent pathways, therefore, holds great promise 
as a therapeutic strategy for a variety of kidney diseases. 
 
Apolipoproteins are important for the formation of protein–lipid complexes and have a key 
role in transporting otherwise insoluble lipids within the body. A common feature of 
apolipoproteins is the presence of tandem 22-mer repeating domains in exon 4.191  When 
these sequences are folded into an alpha-helix, they produce a structure with opposing 
polar and nonpolar faces.192 Synthetic amphipathic helical peptides (SAHPs) are able to 
replicate structural motifs of apolipoproteins that are also able to modulate interactions 
with scavenger receptors such as CD36.28,193 In a mouse model of 5/6 nephrectomy with 
continuous angiotensin II infusion, treatment with the SAHP 5A resulted in preservation of 
kidney function with reduced glomerulosclerosis, interstitial fibrosis, and albuminuria 
compared to controls41. Although the 5A peptide affects other scavenger receptors (SR-Bl/ll) 
in addition to CD36, no benefit of 5A administration in the injury model was seen in 
CD36-deficient mice, suggesting a dominant role of CD36 in disease progression.41  SAHPs 
with more targeted activity against CD36 (ELK-SAHPs) have also been developed. Of these, 
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ELK-B has been shown to inhibit pulmonary inflammation and dysfunction in a sepsis 
model.194 Although blockade of CD36-dependent pathways in the kidney and lung might be 
beneficial, the effect of this blockade on other tissues that express CD36 remains unclear.  
 
Cyclic azopeptides are another class of peptidomimetic therapeutics that can be to target 
CD36.195 The azapeptide EP80317 targets the residues Gln155–Lys183 and has shown 
impressive efficacy in reducing disease and altering pathogenic mechanisms in experimental 
models of atherosclerosis and myocardial infarction.31,196 The efficacy of EP80317 in kidney 
injury is currently under investigation. 
 
[H2] Activating mitochondrial CD36  
Evidence suggests that fully modified CD36 translocates to the cytoplasmic membrane and 
mediates fatty acid uptake and inflammatory responses.81,197 In proximal tubular cells, 
increased levels of fatty acids lead to defects in mitochondrial respiration, reduced FAO and 
intracellular lipid deposition, causing renal fibrosis.40,164,198  Thus, activation of 
mitochondrial CD36, which enhances FAO, might restore these metabolic defects (FIG. 3). 
Inhibition of CD36 protein modifications by genetic or pharmacologic approaches could 
potentially result in increased levels of mitochondrial CD36 and, therefore  increased 
shuttling of fatty acids towards oxidation, which might switch fatty acids from an 
accumulation to a consumption phenotype and protect against kidney fibrosis.   
 
[H1] Conclusions 
CD36 has important roles in lipid homeostasis, metabolic inflammation, reprogramming of 
energy metabolism, apoptosis and kidney fibrosis. The expression and intracellular location 
of CD36 is regulated by its multiple ligands in transcription and post-translational 
modifications. Cross-talk between CD36 ligands, binding partners and signalling pathways; 
and between macrophages and kidney cells; leads to inflammation, apoptosis and/or energy 
reprogramming. These effects represent important molecular mechanisms for the 
development of CKD that warrant further investigation. The development of novel CD36 
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peptides have demonstrated efficacy in slowing the progression of CKD. Given the cell 
specific effects of CD36 and its ubiquitous expression in several tissues, future development 
of new CD36 peptides to target specific sites on the receptor and in select cell populations 
will limit off target effects and improve its efficacy in different kidney diseases.  
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Key Points  
 CD36 is a multifunctional receptor for long-chain fatty acids, oxidized lipids, advanced 
oxidation protein products, thrombospondin and advanced glycation end products 
 CD36 is expressed in a wide variety of kidney cells such as PTECs, mesangial cells, 
podocytes and monocytes/macrophages 
 The expression and intracellular location of CD36 is regulated by multiple ligands 
with roles in gene transcription and post-translational modifications  
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 CD36 is involved in lipid accumulation, inflammation, energy reprograming, 
apoptosis and kidney fibrosis through activation of Toll-like receptors, Na+/K+ATPase, 
the NLRP3 inflammasome, PKC-NAPDH oxidase, Scr/Lyn/Fyn and MAPK kinases, and 
TGF-β signalling pathways 
 Circulating soluble CD36 correlates with tissue CD36 expression and could be a 
biomarker for progression of chronic kidney disease 
 Experimental studies have demonstrated that blockade or knockout of CD36 can 
prevent kidney injury, suggesting that CD36 could be a novel therapeutic target for 
the prevention of kidney fibrosis 
Figure 1 | CD36 structure and post-translational modifications. CD36 has two 
transmembrane domains and two small cytoplasmic tails that contain four 
palmitoylation sites. The C-terminus contains two ubiquitination sites and the 
N-terminal transmembrane domain contains two motifs that are responsible for 
dimerization. The large extracellular loop contains ten N-linked glycosylation sites 
and two phosphorylation sites. A variety of ligands bind to CD36 via the hydrophobic 
binding pocket (entrance 1). Crystal structure studies also suggest that CD36 might 
have a second entrance (entrance 2) for fatty acid transport. CLESH, CD36, LIMP-2, 
Emp sequence homology domain. 
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Figure 2 | CD36 ligand and signal transduction pathways with roles in chronic 
kidney disease progression. Binding of a variety of ligands to CD36 on the plasma 
membrane initiates assembly of a complex of CD36 and Toll-like receptor 4 (TLR4) 
and TLR6; TLR2 and TLR6; or Na+/K+-ATPase. This complex activates NF-κB, the 
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NLRP3 inflammasome, protein kinase c (PKC)-NAPDH oxidase, Scr/Lyn/Fyn and 
mitogen-activated protein kinases (MAPK), and transforming growth factor-β 
(TGF-β)-specific cell signalling pathways. Activation of these pathways has been 
shown in kidney reanl cells (green), macrophages (red) or both cell types (yellow). 
These processes result in lipid accumulation, metabolic inflammation, apoptosis, 
energy metabolism reprogramming and renal fibrosis. ACE, angiotensin-converting 
enzyme; AGEs, advanced glycation end-products; AGT, angiotensinogen; Ang ll, 
angiotensin ll; AOPPs, advanced oxidation protein products; AT1, angiotensin II type 
1 receptor; ERK, extracellular-regulated kinase; CCL5, C-C omotif chemokine 5; 
CPT1, carnitine palmitoyl transferase; FAO, fatty acid oxidation; IL, interleukin;  ox, 
oxidized; MCP-1, monocyte chemoattractant protein-1; NF-kB, nuclear factor-kB; 
RAS, renin–angiotensin system; TNF, tumour necrosis factor; PPARα, peroxisome 
proliferator-activated receptor ; PPARGC1α, PPARγ  coactivator 1α ; ox-HDL, 
oxidized high density lipoprotein; ox-LDL, oxidized low density lipoprotein; ROS, 
reactive oxygen species; TGF-β, transforming growth factor β. 
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Figure 3 | Post-translational modifications regulate CD36 distribution and 
function. Fully-modified CD36 translocates to the plasma membrane and mediates 
fatty acid uptake, oxidative stress and inflammatory responses by triggering 
inflammatory signalling (not shown). Post-translational modifications may promote 
dimerization of CD36 and then increase fatty acid load. Increased amounts of 
intracellular fatty acids lead to defects in mitochondrial respiration in proximal tubule 
cells with reduced fatty acid oxidation (FAO) and increased intracellular lipid 
deposition, resulting in renal fibrosis. Metabolic defects in FAO might be restored by 
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activating mitochondrial CD36, which enhances fatty acid oxidation.  
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Table 1 | Ligands and roles of CD36 in kidney and other tissues 
 
Cell type CD36 ligand Roles Refs.   
Proximal tubule 
epithelial cells 
Fatty acids ATP production, lipid 
accumulation,apoptosis 
10,161 
albumin Fibrosis 122 
AGEs Apoptosis 10 
AOPPs Inflammation, apoptosis 134 
Ox-LDL Inflammation, apoptosis, 
ROS production 
11,15 
Ox-HDL Inflammation, apoptosis, 
ROS production 
131 
Monocytes and/or 
macrophages 
Ox-LDL  Foam cell formation, ROS 
production, lipid 
accumulation,apoptosis 
15,19,20,199 
Serum amyloid A Inflammation 29 
AGEs Inflammation, ROS 
production, lipid 
accumulation 
143,144 
Thrombospondin 1 Inflammation, apoptosis 148 
Porphyromonas gingivalis Foam cell formation 147 
Oxidized phospholipids Apoptosis 21 
Podocytes Fatty acids lipid accumulation, 
apoptosis, ROS production 
12,138,190 
Mesangial cells Ox-HDL Inflammation, apoptosis 154 
Cardiomyocytes Fatty acids ATP production 37 
Vascular endothelial 
cells 
Fatty acids ATP production 45 
Ox-LDL  Foam cell formation, lipid 
accumulation, inflammation 
200 
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